# The Influence of Extracellular Citrate in Physiological Concentration on the Proliferation of Malignant Melanoma

**Authors:** Konstantin Drexler, Barbara Schwertner, Veronika Zenderowski, Laura Schreieder, Dennis Christoph Harrer, Mark Berneburg, Edward Geissler, Maria Mycielska, Sebastian Haferkamp

PMC · DOI: 10.1111/jcmm.71082 · Journal of Cellular and Molecular Medicine · 2026-03-02

## TL;DR

Extracellular citrate promotes melanoma cell growth through a transporter called pmCiC, and blocking this transporter with gluconate can stop this growth.

## Contribution

The study shows that extracellular citrate supports melanoma proliferation via pmCiC and that gluconate can inhibit this process.

## Key findings

- pmCiC was expressed in 58.2% of primary melanomas and 76.5% of metastases, but only 22.2% of benign nevi.
- Melanoma cells with pmCiC showed increased proliferation when exposed to citrate, which was blocked by gluconate.
- Extracellular citrate uptake via pmCiC contributes to melanoma pathogenesis, and its inhibition suppresses citrate-induced proliferation.

## Abstract

Cancer cells rely on citrate for multiple metabolic processes, suggesting that limiting the availability of extracellular citrate may represent a novel therapeutic strategy. The plasma membrane citrate transporter (pmCiC) has been implicated in the pathogenesis of several cancers before, and its activity can be inhibited by gluconate. Tissue samples from patients were stained, and pmCiC expression was analysed and correlated with clinical course. Melanoma cells were treated with or without citrate in physiological concentration and with or without gluconate, a pmCiC inhibitor. Cell proliferation rates were subsequently measured. pmCiC expression was observed in 58.2% of primary melanomas and 76.5% of melanoma metastases, but only in 22.2% of benign nevi. However, pmCiC expression did not correlate with the response to novel melanoma‐specific therapies. In the presence of pmCiC, melanoma cells exhibited significantly increased proliferation when exposed to extracellular citrate. This effect was blocked by the addition of gluconate. Extracellular citrate uptake via pmCiC appears to contribute to the pathogenesis of malignant melanoma. Notably, inhibition of pmCiC by gluconate effectively suppressed citrate‐induced proliferation.

## Linked entities

- **Chemicals:** citrate (PubChem CID 31348), gluconate (PubChem CID 6419706)
- **Diseases:** malignant melanoma (MONDO:0005105), melanoma (MONDO:0005105)

## Full-text entities

- **Genes:** PRAME (PRAME nuclear receptor transcriptional regulator) [NCBI Gene 23532] {aka CT130, MAPE, OIP-4, OIP4}, SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, BRAF (B-Raf proto-oncogene, serine/threonine kinase) [NCBI Gene 673] {aka B-RAF1, B-raf, BRAF-1, BRAF1, NS7, RAFB1}, SLC13A5 (solute carrier family 13 member 5) [NCBI Gene 284111] {aka DEE25, EIEE25, INDY, NACT, mIndy}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}
- **Diseases:** breast cancers (MESH:D001943), melanoma metastases (MESH:D009362), breast, gastric, pancreatic, lung, prostate and urothelial cancer (MESH:C537243), benign nevi (MESH:D009506), cytotoxic (MESH:D064420), skin cancer (MESH:D012878), gastric cancers (MESH:D013274), Merkel cell carcinoma (MESH:D015266), Malignant Melanoma (MESH:D008545), lung, prostate and urothelial cancer (MESH:D011471), pancreatic cancers (MESH:D010190), pmCiC (MESH:C536778), Tumour (MESH:D009369)
- **Chemicals:** L-glutamine (MESH:D005973), Citrate (MESH:D019343), glucose (MESH:D005947), H2O2 (MESH:D006861), Ca2+ (-), haematoxylin (MESH:D006416), penicillin (MESH:D010406), sodium (MESH:D012964), fatty acid (MESH:D005227), water (MESH:D014867), Gluconate (MESH:C030691), ethanol (MESH:D000431), Paraffin (MESH:D010232), DPBS (MESH:C012939), lactate (MESH:D019344), xylol (MESH:D014992), calcium gluconate (MESH:D002125), streptomycin (MESH:D013307)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mycoplasma (genus) [taxon 2093], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** DIA 39 — Mus musculus (Mouse), Hybridoma (CVCL_XX77), SCL13A5 — Homo sapiens (Human), Skin squamous cell carcinoma, Cancer cell line (CVCL_A789), IGR 39 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_2076), pmCiC — Homo sapiens (Human), Frontotemporal dementia and/or amyotrophic lateral sclerosis 1, Induced pluripotent stem cell (CVCL_Y959)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953189/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953189/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953189/full.md

---
Source: https://tomesphere.com/paper/PMC12953189